Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 19, 2014 08:30 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals Initiates Pharmacokinetic and Pharmacodynamics Clinical Study of CPX-351

EWING, N.J., Aug. 19, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
August 07, 2014 16:01 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals Announces Business Update and Second Quarter 2014 Financial Results

EWING, N.J., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported business...
July 31, 2014 08:30 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals to Report Second Quarter 2014 Financial Results on August 7, 2014

EWING, N.J., July 31, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
July 17, 2014 08:00 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals Provides Update on CPX-351 and Technology Platform at Analyst Day

New Applications Announced for Proprietary CombiPlex Platform Geared Towards Molecularly Targeted Therapies CPX-351 to be Explored in Additional Patient Populations, Including New Acute...
July 02, 2014 08:30 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals Announces Analyst Day and Webcast

EWING, N.J., July 2, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
June 27, 2014 08:30 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals to be Added to Russell MicroCap Index

EWING, N.J., June 27, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, announced that...
June 17, 2014 16:30 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals to Present at Upcoming Conferences in June

EWING, N.J., June 17, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
June 11, 2014 08:30 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals Announces Data and Safety Monitoring Board Recommendation to Continue Phase 3 Study of CPX-351

EWING, N.J., June 11, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
June 04, 2014 08:30 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals Reaches 75% Enrollment Milestone in Phase 3 Study of CPX-351

EWING, N.J., June 4, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it...
May 27, 2014 08:30 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals Announces Publication of Positive Phase 2 Data With CPX-351 in Acute Myeloid Leukemia Patients

EWING, N.J., May 27, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), announced the publication of the Phase 2 study evaluating CPX-351 in newly diagnosed older patients with...